| Poststroke depression biomarkers: a narrative review OA Levada, AS Troyan Frontiers in Neurology 9, 362121, 2018 | 74 | 2018 |
| Insulin-like growth factor-1: a possible marker for emotional and cognitive disturbances, and treatment effectiveness in major depressive disorder OA Levada, AS Troyan Annals of general psychiatry 16 (1), 38, 2017 | 50 | 2017 |
| Cognitive-functional relationships in major depressive disorder: Crucial data from a Ukrainian open-label study of vortioxetine versus escitalopram OA Levada, AS Troyan Journal of affective disorders 250, 114-122, 2019 | 43 | 2019 |
| Plasma brain-derived neurotrophic factor as a biomarker for the main types of mild neurocognitive disorders and treatment efficacy: a preliminary study OA Levada, NV Cherednichenko, AV Trailin, AS Troyan Disease markers 2016, 2016 | 34 | 2016 |
| The diagnostic value of the combination of serum brain-derived neurotrophic factor and insulin-like growth factor-1 for major depressive disorder diagnosis and treatment efficacy AS Troyan, OA Levada Frontiers in Psychiatry 11, 514735, 2020 | 18 | 2020 |
| Serum insulin-like growth factor-1 as a potential marker for MDD diagnosis, its clinical characteristics, and treatment efficacy validation: data from an open-label … OA Levada, AS Troyan, IY Pinchuk BMC psychiatry 20, 1-10, 2020 | 15 | 2020 |
| Major depressive disorder and accelerated aging from a peripheral IGF-1 overexpression perspective OA Levada, AS Troyan Medical Hypotheses 138, 109610, 2020 | 12 | 2020 |
| neuropsychiatric symptoms in Patients with the Main etiological Types of Mild neurocognitive Disorders: a hospital-Based case–control study OA Levada, NV Cherednichenko, AS Troyan Frontiers in Psychiatry 8, 251105, 2017 | 6 | 2017 |
| AGE-ADJUSTED NORMATIVE DATA AND DISCRIMINATIVE VALIDITY OF COGNITIVE TESTS IN THE UKRAINIAN ADULT PATIENTS WITH MAJOR DEPRESSIVE DISORDER O Troyan, O Levada Modern Medical Technology, 4-14, 2021 | 3 | 2021 |
| Specific Cognitive–Psychopathological Phenotypes in Patients With Early Stages of Subcortical Vascular Neurocognitive Disorders: A Hospital-Based Case–Control Study OA Levada, AS Troyan, NV Cherednichenko Journal of Geriatric Psychiatry and Neurology 31 (5), 256-264, 2018 | 2 | 2018 |
| Cognitive impairment in patients with major depressive disorder: current approaches OA Levada, AS Trojan NejroNews 1, 9-12, 2016 | 2 | 2016 |
| P. 317 Serum insulin-like growth factor-1 levels in patients with major depressive disorder and change after two monthsvortioxetine treatment O Troian, O Levada European Neuropsychopharmacology 31, S58-S59, 2020 | 1 | 2020 |
| Associations between cognitions and functional decline in patients with major depressive disorder AS Troyan, OA Levada Archives of psychiatry 25 (2), 114-115, 2019 | 1 | 2019 |
| Ïñèõ³÷í³ ðîçëàäè ³ç ñîìàòè÷íèìè ñèìïòîìàìè: ì³ñöå â ñó÷àñíèõ êëàñèô³êàö³ÿõ, äåô³í³ö³¿, ä³àãíîñòèêà òà ë³êóâàííÿ ÎÀ Ëåâàäà, ÎÑ Òðîÿí Àðõ³â ïñèõ³àòð³¿, 6-14, 2018 | 1 | 2018 |
| P. 018 Vortioxetine vs escitalopram regarding cognitive and functional recovery in the Ukrainian cohort of patients with major depressive disorder: An 8-week study O Troian, O Levada European Neuropsychopharmacology 29, S32, 2019 | | 2019 |
| P300 parameters as markers for early stages of subcortical vascular neurocognitive disorder and treatment efficacy OA Levada, NV Cherednichenko, AS Troyan European Neuropsychopharmacology 27, S1037-S1038, 2017 | | 2017 |
| Research Article Plasma Brain-Derived Neurotrophic Factor as a Biomarker for the Main Types of Mild Neurocognitive Disorders and Treatment Efficacy: A Preliminary Study OA Levada, NV Cherednichenko, AV Trailin, AS Troyan | | 2016 |
| Åï³äåì³îëîã³÷í³ àñïåêòè âåëèêîãî ñóäèííîãî íåéðîêîãí³òèâíîãî ðîçëàäó çà îñòàíí³ äåñÿòü ðîê³â: ñòèñëèé îãëÿä ÎÀ Ëåâàäà, ÀÑ Òðîÿí Àðõ³â ïñèõ³àòð³¿, 50-54, 2016 | | 2016 |
Oleg LevadaZaporizhzhia State Medical and Pharmaceutical UniversityVerified email at zsmu.edu.ua
